AUTHOR=Wenzel Lisa , Heesen Christoph , Peper Julia , Grentzenberg Kristina , Faßhauer Edeltraud , Scheiderbauer Jutta , Thale Frithjof , Meyer Björn , Köpke Sascha , Rahn Anne Christin 

TITLE=An interactive web-based programme on relapse management for people with multiple sclerosis (POWER@MS2) - development, feasibility, and pilot testing of a complex intervention

JOURNAL=Frontiers in Neurology

VOLUME=Volume 13 - 2022

YEAR=2022

URL=https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2022.914814

DOI=10.3389/fneur.2022.914814

ISSN=1664-2295

ABSTRACT=Introduction: Despite the lack of high-quality evidence regarding its effectiveness, corticosteroid therapy is recommended as the standard treatment of acute relapses in multiple sclerosis. There is an urgent need to provide patients with evidence-based and comprehensible information on relapse management and to actively involve patients in relapse treatment decisions. Web-based decision support on relapse management could be an effective measure to empower people with multiple sclerosis making informed treatment decisions.
Objectives: To develop a web-based programme on relapse management for people with multiple sclerosis and evaluate the feasibility and acceptability of the intervention. 
Methods: The study followed the first two phases of the UK Medical Research Council Framework for complex interventions. The first phase involved the development of an interactive web-based programme on relapse management. The second phase focused on the feasibility and pilot testing of the programme with people with multiple sclerosis and experts. Data was obtained using questionnaires with closed- and open-ended questions as well as qualitative semi-structured telephone interviews. Quantitative data was analysed descriptively, whereas qualitative data was clustered by topic.  
Results: Feasibility of the intervention programme was tested with 10 people with multiple sclerosis and 10 experts. Feasibility testing indicated good practicability and acceptance of the content. After revision, the programme was piloted with 7 people with multiple sclerosis and 3 experts. The results showed good acceptance in both groups. Based on the feedback, a final revision was performed.
Conclusion: Feasibility and pilot testing indicated good user-friendliness, acceptance, and practicability of the programme. The programme is currently evaluated in a randomized controlled trial (Registration Number on ClinicalTrials.gov: NCT04233970). It is expected that the programme will have a positive impact on patients’ relapse management and strengthen their autonomy and participation.